TD Asset Management
BLTE

TD Asset Management’s Belite Bio BLTE Stock Holding History

TD Asset Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Sell
13,010
-20,400
-61% -$3.13M ﹤0.01% 971
2026
Q1 		$5.33M Buy
+33,410
New +$5.62M ﹤0.01% 782

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Asset Management's BLTE Position: Q2 2026 in Review

TD Asset Management reduced its Belite Bio (BLTE) stake by 61% in Q2 2026, selling an estimated $3.13M and leaving 13,010 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #971.

TD Asset Management first reported a position in BLTE in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.33M in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • TD Asset Management held 13,010 shares of Belite Bio worth $2M as of Q2 2026.
  • TD Asset Management sold 20,400 Belite Bio shares in Q2 2026, an estimated $3.13M.
  • Belite Bio made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #971 holding.
  • TD Asset Management first reported a position in Belite Bio in Q1 2026 and has held it in 2 quarters since.
  • TD Asset Management's Belite Bio position peaked at $5.33M in Q1 2026.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.